Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD).
UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidinium bromide --- a long-acting muscarinic antagonist (LAMA)--- and vilanterol, a long-acting beta2 agonist which is administered using the Ellipta inhaler.
The application proposes the proprietary name Anora Ellipta and has been submitted to the US Food and Drug Administration for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Applications for UMEC/VI are also planned in the European Union and in other countries next year.
FSTE 100 company GSK is a leading research-based pharmaceutical and healthcare company.
Theravance is a biopharmaceutical company which collaborates with a number of pharmaceutical organisations.
RD
-
8 of the best lakeside properties for saleThe best lakeside properties – from a house on the southeastern shore of Loch Lomond, to a 15th-century hall overlooking a lake in King’s Lynn, Norfolk
-
Gold’s allure and why you should never 'pay a premium for graded coins'It is easy to become distracted by the beauty of gold, but remember why you buy it, says Dominic Frisby
